264 related articles for article (PubMed ID: 11426495)
1. Behcet's disease in a patient with chronic myelogenous leukemia under hydroxyurea treatment: a case report and review of the literature.
Vaiopoulos G; Terpos E; Viniou N; Nodaros K; Rombos J; Loukopoulos D
Am J Hematol; 2001 Jan; 66(1):57-8. PubMed ID: 11426495
[TBL] [Abstract][Full Text] [Related]
2. Behçet's disease induced by interferon therapy for chronic myelogenous leukemia.
Segawa F; Shimizu Y; Saito E; Kinoshita M
J Rheumatol; 1995 Jun; 22(6):1183-4. PubMed ID: 7674251
[TBL] [Abstract][Full Text] [Related]
3. Development of large genital ulcer due to hydroxyurea treatment in a patient with chronic myeloid leukemia and Behcet's disease.
Karincaoglu Y; Kaya E; Esrefoglu M; Aydogdu I
Leuk Lymphoma; 2003 Jun; 44(6):1063-5. PubMed ID: 12854911
[TBL] [Abstract][Full Text] [Related]
4. Behçet's disease in patients with chronic myelogenous leukemia: possible role of interferon-alpha treatment in the occurrence of Behçet's symptoms.
Budak-Alpdoğan T; Demirçay Z; Alpdoğan O; Direskeneli H; Ergun T; Bayik M; Akoğlu T
Ann Hematol; 1997 Jan; 74(1):45-8. PubMed ID: 9031616
[TBL] [Abstract][Full Text] [Related]
5. Hydroxyurea induced leg ulcers.
Abhyankar D; Shende C; Saikia T; Advani SH
J Assoc Physicians India; 2000 Sep; 48(9):926-7. PubMed ID: 11198798
[TBL] [Abstract][Full Text] [Related]
6. [Bilateral leg ulcers with pathologic evidence of small vessel vasculitis by skin biopsy during hydroxyurea therapy of chronic myelogenous leukemia].
Tomiyama J; Yano K; Uchino S; Ito T; Kudo H; Irimajiri J; Ohkubo H; Kanazawa A; Kawahara Y
Rinsho Ketsueki; 1997 Mar; 38(3):231-3. PubMed ID: 9095664
[TBL] [Abstract][Full Text] [Related]
7. Reversible leg ulcer due to hydroxyurea in a case of chronic myeloid leukemia.
Tripathi AK; Ahmad R; Sawlani KK
J Assoc Physicians India; 2003 Oct; 51():1014-5. PubMed ID: 14719596
[TBL] [Abstract][Full Text] [Related]
8. [Chronic myelogenous leukemia with long-term hypoplasia induced by alpha-interferon and hydroxyurea].
Motomura S; Sakai R; Tomita N; Fujimaki K; Hattori M; Fujisawa S; Mohri H; Takahashi N; Maruta A; Kodama F; Okubo T
Rinsho Ketsueki; 1998 Apr; 39(4):302-7. PubMed ID: 9597898
[TBL] [Abstract][Full Text] [Related]
9. [Pure red cell aplasia occurring during the course of chronic myelogenous leukemia].
Yasuyama M; Kawauchi K; Takei K; Ogasawara T; Ohkawa S
Rinsho Ketsueki; 2004 Jan; 45(1):66-71. PubMed ID: 14999937
[TBL] [Abstract][Full Text] [Related]
10. [Bilateral ankle ulcers associated with hydroxyurea therapy for chronic myelogenous leukemia].
Masuoka H; Kobayashi M; Kaito K; Yoshida M; Sekita T; Saeki A; Nishiwaki K; Shimada T; Ochiai S; Ootsubo H
Rinsho Ketsueki; 1995 Feb; 36(2):156-8. PubMed ID: 7715088
[TBL] [Abstract][Full Text] [Related]
11. Perimalleolar ulcers in hydroxyurea treated patients with concomitant chronic venous disease: diagnostic pitfalls.
Jain V; Gupta K; Nagpal N
J Coll Physicians Surg Pak; 2005 Oct; 15(10):658-60. PubMed ID: 19810313
[TBL] [Abstract][Full Text] [Related]
12. [Myositis caused by hydroxyurea in a patient with chronic myelogenous leukemia].
Ikeda K; Mita M; Ishibashi T; Shichishima T; Maruyama Y
Rinsho Ketsueki; 1998 Sep; 39(9):676-9. PubMed ID: 9796402
[TBL] [Abstract][Full Text] [Related]
13. Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase.
Warren E; Ward S; Gordois A; Scuffham P
Clin Ther; 2004 Nov; 26(11):1924-33. PubMed ID: 15639704
[TBL] [Abstract][Full Text] [Related]
14. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase.
Kantarjian H; O'Brien S; Cortes J; Shan J; Giles F; Garcia-Manero G; Verstovsek S; Faderl S; Rios MB; Talpaz M
Cancer; 2003 Oct; 98(7):1430-7. PubMed ID: 14508830
[TBL] [Abstract][Full Text] [Related]
15. Hydroxyurea-induced fever in a patient with chronic myelogenous leukemia.
Tsurumi H; Goto H; Hara T; Moriwaki H
Int J Hematol; 2000 Oct; 72(3):386-7. PubMed ID: 11186000
[No Abstract] [Full Text] [Related]
16. [Anhidrosis during long-term hydroxyurea therapy in a patient with chronic myelogenous leukemia].
Takagi K; Nakamura T; Misaki H; Ueda T
Rinsho Ketsueki; 2000 Nov; 41(11):1214-9. PubMed ID: 11193442
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of alpha interferon and hydroxyurea in late phase refractory myeloproliferative disease.
Litam PP; Landaw SA; Zamkoff KW
Haematologia (Budap); 1994; 26(2):87-90. PubMed ID: 7890266
[TBL] [Abstract][Full Text] [Related]
18. Thrombotic microangiopathy associated with alpha-interferon therapy for chronic myeloid leukaemia.
Galesic K; Bozic B; Racic I; Scukanec-Spoljar M
Nephrology (Carlton); 2006 Feb; 11(1):49-52. PubMed ID: 16509932
[TBL] [Abstract][Full Text] [Related]
19. Gangrene of the toes in a patient with chronic myelogenous leukemia after long-term hydroxyurea therapy.
Leo E; Krämer A; Hochhaus A; Krasniqi F; Hehlmann R; Ho AD
Ann Hematol; 2002 Aug; 81(8):467-9. PubMed ID: 12224005
[TBL] [Abstract][Full Text] [Related]
20. [Chronic myelogenous leukemia following therapy for pineal germinoma].
Noda M; Shoda T; Takimoto Y; Okita H
Rinsho Ketsueki; 2004 Jan; 45(1):72-4. PubMed ID: 14999938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
